Cord Blood Banking Market to Reach $49.85B

The concept of using cord blood for medical treatment dates back to 1988, when the first successful cord blood transplant was performed on a child with Fanconi anemia. This groundbreaking procedure demonstrated the potential of the hematopoietic stem cells found in umbilical cord blood, which were previously discarded as medical waste. The first public cord blood bank was established in 1992 by the New York Blood Center, allowing for altruistic donations to be used by any matching patient in need. This was soon followed by the emergence of private cord blood banks, which offer families the option to store their baby's cord blood exclusively for their own use, often marketed as a form of "biological insurance." Families who opt for private banking pay an initial collection fee that can be thousands of dollars, plus annual storage fees of several hundred dollars. In contrast, donating to a public bank is free of charge, and the cord blood is made available for anyone who is a match or for medical research. Currently, stem cells from cord blood are used in the treatment of over 80 diseases, including various cancers, blood disorders like sickle cell anemia, and some immune system deficiencies. These stem cells have the advantage of being less likely to be rejected by the body compared to adult stem cells from bone marrow. The U.S. Food and Drug Administration (FDA) regulates cord blood banks, with public banks held to more stringent standards as the stored cord blood is considered a "drug." In April 2023, the FDA approved a procedure to multiply cord blood stem cells, a significant step in overcoming the limitation of the small number of stem cells in a single umbilical cord. Beyond established treatments, research is actively exploring the use of cord blood in regenerative medicine for conditions like autism, cerebral palsy, and diabetes. This ongoing research continues to expand the potential therapeutic applications for this valuable biological resource.